Chagas disease is the most important protozoan infection in the Americas, and constitutes a
significant public health concern throughout the world. Development of new medications …

Introduction Chagas disease (CD) imposes social and economic burdens, yet the available
treatments have limited efficacy in the disease's chronic phase and cause serious adverse …

Millions who live in Latin America and sub-Saharan Africa are at risk of trypanosomatid
infections, which cause Chagas disease and human African trypanosomiasis (HAT) …

Trypanosoma cruzi naturally infects a broad range of mammalian species and frequently
results in the pathology that has been most extensively characterized in human Chagas …

There is an urgent need for new treatments for Chagas disease, a parasitic infection which
mostly impacts South and Central America. We previously reported on the discovery of …

Prodrugs are derivatives with superior properties compared with the parent active
pharmaceutical ingredient (API), which undergo biotransformation after administration to …

Parasitic diseases still compromise human health. Some of the currently available
therapeutic drugs have limitations considering their adverse effects, questionable efficacy …

During Trypanosoma cruzi infection, macrophages phagocytose parasites and remove
apoptotic cells through efferocytosis. While macrophage 1 (M1) produces proinflammatory …

Continuous efforts are being directed toward the employment of boron in drug design due to
its advantages and unique characteristics including a plethora of target engagement modes …

Due to the lack of specific vaccines, management of the trypanosomatid-caused neglected
tropical diseases (sleeping sickness, Chagas disease and leishmaniasis) relies exclusively …